This research develops hybrid lipo-polymeric nanoparticles that overcome major limitations of current mRNA vaccine technology. The particles can be freeze-dried, rapidly loaded with mRNA, and simultaneously deliver therapeutic drugs. Their flexibility improves vaccine storage and distribution while enabling powerful combination therapies, including enhanced cancer treatments with improved survival in preclinical models.

This research focuses on strengthening fragile mRNA molecules to create vaccines that are more stable, effective, and easier to distribute. By modifying mRNA structure to resist degradation, vaccines could be stored at higher temperatures and maintain potency, expanding access—especially in low-resource regions—and improving global readiness for future pandemics.

This research aims to solve the major weakness of mRNA vaccines—the need for constant cold storage—by packaging them inside ultra-stable protein “boxes” called encapsulins. These naturally robust containers protect mRNA in extreme environments. A working prototype now exists, offering the potential for globally distributable, freezer-free vaccines that remain effective anywhere.